BioMarin Pharmaceutical Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BioMarin Pharmaceutical Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 95.3 times by its yearly operating cash. Higher than 97% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $53 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $49 tied up three years earlier. More money tied up than 94% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.9 times. Higher than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$165Over the last 3 years, every $100 of reported profit came with $165 of operating cash.
Higher than 62% of Healthcare companies in United States.
Self-Funding Ratio
4.9×Over the last 3 years its own operating cash covered its investment spending (capex) 4.9 times.
Higher than 87% of Healthcare companies in United States.
Cash Locked Ratio
$53For every $100 of sales, $53 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $49 tied up three years earlier.
More money tied up than 94% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$18Sales grew 54% in 3 years; of every extra $100 of sales, $18 became extra profit.
Lower than 51% of Healthcare companies in United States.
Asset Productivity Ratio
+54% / +19%In 3 years sales changed by +54% while total assets changed by +19%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
95.3×Debt due within a year is covered 95.3 times by its yearly operating cash.
Higher than 97% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Lower than 51% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 70% of Healthcare companies in United States.
Tangible Net Worth Ratio
93%Of every $100 of net worth, $93 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 77% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
BioMarin Pharmaceutical Inc. owes $0.46 for every $1 it owns. Net profit fell 18% in the year to Dec 2025, and grew 35% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
151.2Investors pay $151.2 for every $1 of BioMarin Pharmaceutical Inc.'s yearly profit, higher than 95% of Healthcare companies in United States.
P/B ratio
1.71The share price is 1.71 times BioMarin Pharmaceutical Inc.'s book value per share, lower than 63% of Healthcare companies in United States.
Market cap
$10.8 BThe total market value of all of BioMarin Pharmaceutical Inc.'s shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$6.3 BWhat BioMarin Pharmaceutical Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$32.66Net worth divided by the number of shares. The share price of $55.95 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
1.2%BioMarin Pharmaceutical Inc. earned 1.2% on its shareholders' money over the last year, higher than 76% of Healthcare companies in United States.
Owes vs Owns
0.46×BioMarin Pharmaceutical Inc. owes $0.46 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Dividend yield
NoneBioMarin Pharmaceutical Inc. does not currently pay a dividend.
Revenue growth
+13%Revenue rose 13% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Profit growth
-18%Net profit fell 18% in the year to Dec 2025, and grew 35% a year on average over 3 years.
Profit margin
10.8%BioMarin Pharmaceutical Inc. keeps $11 of every $100 of revenue as net profit.
Cash quality
2.4×Cash from BioMarin Pharmaceutical Inc.'s business was 2.4× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
37.6×BioMarin Pharmaceutical Inc.'s operating profit covered its interest costs 37.6 times in the year to Dec 2025.
Cash vs debt
Net cashBioMarin Pharmaceutical Inc. held $955 M more cash than debt (net cash) at Dec 2025.
Questions
What is BioMarin Pharmaceutical Inc.'s P/E ratio?
Investors pay $151.2 for every $1 of BioMarin Pharmaceutical Inc.'s yearly profit, higher than 95% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For BioMarin Pharmaceutical Inc.: $10.8 B ÷ $6.3 B (30 Jun 2026) = 1.7.
What is BioMarin Pharmaceutical Inc.'s return on equity?
BioMarin Pharmaceutical Inc. earned 1.2% on its shareholders' money over the last year, higher than 76% of Healthcare companies in United States.
How much does BioMarin Pharmaceutical Inc. owe compared with what it owns?
BioMarin Pharmaceutical Inc. owes $0.46 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Does BioMarin Pharmaceutical Inc. pay a dividend?
No. BioMarin Pharmaceutical Inc. does not currently pay a dividend.
Is BioMarin Pharmaceutical Inc.'s revenue growing?
Revenue rose 13% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.